VETO
XPAR
Market cap1.12bUSD
Nov 20, Last price
85.70EUR
1D
-0.70%
1Q
21.56%
Jan 2017
88.23%
IPO
272.61%
Name
Vétoquinol
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Vetoquinol S.A. is a prominent veterinary pharmaceutical enterprise dedicated to the innovation, development, and global commercialization of both medicinal and non-medicinal solutions for animal health. Its operations extend across Europe, the Americas, and the Asia Pacific regions. The company's diverse product portfolio addresses crucial therapeutic areas, including mobility, pain management, and inflammation; dermatological care and hygiene; anti-parasitic treatments; udder health; infectious disease control; reproductive solutions; behavior modification; internal medicine; and cardiovascular-renal support. These offerings cater to a wide spectrum of animals, encompassing livestock such as cattle, sheep, pigs, and poultry, alongside companion animals like dogs. Founded in 1933, Vetoquinol S.A. is headquartered in Lure, France, and functions as a subsidiary of Soparfin SCA.
Related entities
Parent
SOPARFIN
Subsidiaries
VETOQUINOL INTERNATIONAL
Key people
Matthieu Frechin
Chairman of the Board, Chief Executive Officer · since 2023
Alain Masson
Deputy Chief Executive Officer and Head Pharmacist, Group Quality Director · since 2020
Dominique Derveaux
Group Chief Operating Officer · since 2020
Nathalie Arlecchini
Group Human Resources Director · since 2025
Audrey Chanoinat
Director · since 2021
M. Luc Frechin
Director · since 2021
Philippe Arnold
Independent Director · since 2020
Marie-Josephe Baud
Independent Director · since 2020
Louis Champel
Independent Director · since 2020
Anne Graffin
Independent Director · since 2022
Headquarters & legal address
Village
MAGNY-VERNOIS 70200
FR
MAGNY-VERNOIS 70200
FR
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||